Hin Sang Group (International) Holding Co. Ltd.
HHKEX:68930.34
HKD
-0.01
(-4.23%)
ISIN
KYG4590V1023
CUSIP
G4590V102
Return %
Stock
S&P 500
1Y
91.01
14.20
3Y
-9.33
81.12
5Y
3.03
68.34
Capital Structure
HKD
•
in mil. unless spec.Working Capital
HKD
•
in mil. unless spec.Growth Rates
HKD
•
in mil. unless spec.Semi-annual Revenue
HKD
•
in mil. unless spec.Semi-annual Earnings Per Share
HKD
•
in mil. unless spec.Semi-annual Dividends Per Share
HKD
•
in mil. unless spec.Company Description
- CEO
- Lai Man Kwan
- Full Time Employees
- 198
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Seapower Tower Hong Kong Hong Kong
- IPO Date
- Oct 16, 2014
- Website
- hinsanggroup.com
- Similar Companies
- Business
- Hin Sang Group (International) Holding Co. Ltd. engages in the manufacture, marketing, and sale of healthcare products primarily targeting children in Hong Kong and Mainland China. The company operates through four key segments: Product Development, Brand Development and Management, Trading of Goods, and Healthcare. Its Product Development segment develops and sells personal care products, household products, and health supplements under brands including Hin Sang, Tai Wo Tong, Cheers Smart, Care Plus, Shuang Long, and King's Antiseptic. The Brand Development and Management segment handles marketing, sales, distribution, logistics, and delivery for personal care products under brands such as Pahmi, Enear, Vcnic, Zici, and Sunew, while also managing brands for proprietors. The Trading of Goods segment trades and distributes skincare, personal care, and household products sourced from authorized dealers, independent traders, manufacturers, and parallel importers. The Healthcare segment provides Chinese medical healthcare services including treatment and consultation for mothers and children, and develops mother- and child-related health products and medical centers. Founded in 1996, the company is headquartered in Tsim Sha Tsui, Hong Kong and operates across Mainland China, Hong Kong, Macau, Taiwan, and Southeast Asia. It is a subsidiary of Genwealth Group Holding Company Limited. Recent major changes include the company's strategic focus on expanding its presence in the Mainland China market, especially in children's health supplements, leveraging China's three-child policy. Hin Sang Group continues to develop and launch new products under its own brands Hin Sang, Weverse, and Yabune, which combine traditional herbal ingredients with advanced technology, and holds certifications such as HKC and GMP. The group has invested in its Hin Sang Health Medical Industrial Park in Yunfu City, Guangdong Province, enhancing production capacity with fully automated production lines for beverages, convenience foods, and confectionery products, as well as OEM and ODM manufacturing services. It is also upgrading its e-commerce platform to expand online sales, particularly targeting Mainland China customers. Cost containment measures and administrative expense reductions have improved the group's financial performance in recent periods. The company plans to strengthen brand recognition, expand its distribution network by recruiting more distributors, and focus on marketing to respond to changing consumer behavior while maintaining a strong position in the Hong Kong health supplement market. Hin Sang Group maintains a comprehensive product portfolio of health supplements, traditional Chinese medicines, personal care, and household products marketed under multiple proprietary and distributed brands. It also actively engages in Chinese medicine cultural education and eco-industrial development as part of its broader healthcare business strategy. This description reflects Hin Sang Group's diverse operations and recent strategic developments up to 2025.